natgillin/translations-raw huggingface dataset:
Neoclarityn oral solution with food, drink and alcohol Neoclarityn may be taken with or without a meal.
Zdravilo Neoclarityn peroralna raztopina skupaj s hrano, pijačo in alkoholom Zdravilo Neoclarityn se lahko jemlje s hrano ali brez nje.
Neoclarityn oral solution contains sorbitol.
Zdravilo Neoclarityn peroralna raztopina vsebuje sorbitol Neoclarityn peroralna raztopina vsebuje sorbitol.
What Neoclarityn oral solution is and what it is used for What you need to know before you take Neoclarityn oral solution How to take Neoclarityn oral solution Possible side effects
Kaj je zdravilo Neoclarityn in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Neoclarityn Kako jemati zdravilo Neoclarityn Možni neželeni učinki
How to take Neoclarityn orodispersible tablet
Kako jemati zdravilo Neoclarityn orodisperzibilna tableta
If you stop taking Neoclarityn orodispersible tablet If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če ste prenehali jemati zdravilo Neoclarityn orodisperzibilna tableta Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Neoclarityn is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis (see section 5.1) - urticaria (see section 5.1)
Zdravilo Neoclarityn je indicirano pri odraslih in mladostnikih, starih 12 let in več, za lajšanje simptomov: - alergijskega rinitisa (glejte poglavje 5.1) - urtikarije (glejte poglavje 5.1)
Neoclarityn is supplied in blisters comprised of laminate blister film with foil lidding.
Neoclarityn je na voljo v laminatnih pretisnih omotih , ki ga sestavljata film pretisnega, omota in folija, ki ga prekriva.
Neoclarityn tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih zdravilo Neoclarityn v enem dnevnem odmerku 7,5 mg pri odraslih in mladostnikih ni vplivalo na psihomotorične sposobnosti bolnikov.
Do not take Neoclarityn - if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine.
Ne uporabljajte zdravila Neoclarityn - če ste alergični na desloratadin ali katero koli sestavino tega zdravila (navedeno v poglavju 6)
● rash
• driska
If you stop taking Neoclarityn If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če ste prenehali jemati zdravilo Neoclarityn Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
The safety and efficacy of Neoclarityn 0.5 mg/ml oral solution in children below the age of 1 year have not been established.
Varnost in učinkovitost zdravila Neoclarityn 0,5 mg/ml peroralna raztopina pri otrocih, mlajših od 1 leta, nista bili dokazani.
Neoclarityn orodispersible tablet is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Neoclarityn orodisperzibilna tableta se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
The safety and efficacy of Neoclarityn 5 mg film-coated tablets in children below the age of 12 years have not been established.
Varnost in učinkovitost zdravila Neoclarityn 5 mg filmsko obložene tablete pri otrocih, mlajših od 12 let, nista bili dokazani.
In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo.
Ta se je pojavil pri 5,9 % bolnikov, zdravljenih z desloratadinom, in pri 6,9 % bolnikov, zdravljenih s placebom.
Neoclarityn is an antiallergy medicine that does not make you drowsy.
Zdravilo Neoclarityn je zdravilo proti alergiji, ki ne povzroča zaspanosti.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Neoclarityn tablets were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih tablet Neoclarityn poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
The safety and efficacy of Neoclarityn 2.5 mg orodispersible tablets in children below the age of 6 years have not been established.
Varnost in učinkovitost zdravila Neoclarityn 2,5 mg orodisperzibilne tablete pri otrocih, mlajših od 6 let, nista bili dokazani.
Neoclarityn 5 mg orodispersible tablet is light red, speckled, and round with “A” branded on one side.
Neoclarityn 5 mg orodisperzibilne tablete so svetlo rdeče okrogle pikčaste tablete z oznako A na eni strani.
Neoclarityn orodispersible tablet is packed in unit dose blisters in packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 doses of orodispersible tablet.
Neoclarityn orodisperzibilne tablete so na voljo v pretisnih omotih po 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 in 100 orodisperzibilnih tablet.
BOX OF 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 100 TABLETS
ŠKATLA PO 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 100 TABLET
At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri odraslih in mladostnikih za različne indikacije, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku o neželenih učinkih zdravila Neoclarityn poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
Neoclarityn is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Neoclarityn se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
In adult and adolescent patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri odraslih in mladostnikih z alergijskim rinitisom zdravilo Neoclarityn tablete učinkovito lajša simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
Packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 100 tablets.
Pakiranja po 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 ali 100 tablet.
What Neoclarityn contains
Kaj vsebuje zdravilo Neoclarityn
How to store Neoclarityn oral solution Contents of the pack and other information
Shranjevanje zdravila Neoclarityn Vsebina pakiranja in dodatne informacije
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Neoclarityn poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
Neoclarityn tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih tablete Neoclarityn v enem dnevnem odmerku 7,5 mg niso vplivale na psihomotorične sposobnosti bolnikov.
Neoclarityn 0.5 mg/ml oral solution desloratadine
Neoclarityn 0,5 mg/ml peroralna raztopina desloratadin
If you stop taking Neoclarityn oral solution If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če ste prenehali jemati zdravilo Neoclarityn peroralna raztopina Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
How to take Neoclarityn
Kako jemati zdravilo Neoclarityn
This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Neoclarityn orodispersible tablet.
Neoclarityn orodisperzibilne tablete vsebujejo 1,4 mg fenilalanina na 2,5 mg odmerek zdravila.
In patients with allergic rhinitis, Neoclarityn tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri bolnikih z alergijskim rinitisom tablete Neoclarityn učinkovito lajšajo simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
The safety and efficacy of Neoclarityn 5 mg orodispersible tablets in children below the age of 12 years have not been established.
Varnost in učinkovitost zdravila Neoclarityn 5 mg orodisperzibilne tablete pri otrocih, mlajših od 12 let, nista bili dokazani.
Neoclarityn 5 mg film-coated tablets
Neoclarityn 5 mg filmsko obložene tablete
This product contains 2.9 mg of phenylalanine per 5 mg dose of Neoclarityn orodispersible tablet.
Neoclarityn orodisperzibilne tablete vsebujejo 2,9 mg fenilalanina na 5 mg odmerek zdravila.
Neoclarityn 0.5 mg/ml oral solution
Neoclarityn 0,5 mg/ml peroralna raztopina
What Neoclarityn orodispersible tablet looks like and contents of the pack
Izgled zdravila Neoclarityn orodisperzibilna tableta in vsebina pakiranja
In patients with allergic rhinitis, Neoclarityn was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri bolnikih z alergijskim rinitisom zdravilo Neoclarityn učinkovito lajša simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
How to store Neoclarityn
Shranjevanje zdravila Neoclarityn
Neoclarityn given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih zdravilo Neoclarityn v enem dnevnem odmerku 7,5 mg ni vplivalo na psihomotorične sposobnosti bolnikov.
How Neoclarityn works
Kako deluje zdravilo Neoclarityn
Clinical efficacy and safety In a multiple dose trial, Neoclarityn orodispersible tablets were well tolerated.
V preskušanju večkratnega odmerjanja so bolniki zdravilo Neoclarityn orodisperzibilne tablete dobro prenašali.
Neoclarityn 5 mg film-coated tablets desloratadine
Neoclarityn 5 mg filmsko obložene tablete desloratadin
Neoclarityn oral solution is an antiallergy medicine that does not make you drowsy.
Zdravilo Neoclarityn peroralna raztopina je zdravilo proti alergiji, ki ne povzroča zaspanosti.
How to store Neoclarityn orodispersible tablet
Shranjevanje zdravila Neoclarityn orodisperzibilna tableta
Neoclarityn oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap. For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
Neoclarityn peroralna raztopina je na voljo v stekleničkah po 30, 50, 60, 100, 120, 150, 225 in 300 ml, z zaporko, varno za otroke.
What you need to know before you take Neoclarityn oral solution
Kaj morate vedeti, preden boste vzeli zdravilo Neoclarityn peroralna raztopina
Neoclarityn 2.5 mg orodispersible tablets
Neoclarityn 2,5 mg orodisperzibilne tablete
Neoclarityn 5 mg orodispersible tablets
Neoclarityn 5 mg orodisperzibilna tableta
Neoclarityn 2.5 mg orodispersible tablets desloratadine
Neoclarityn 2,5 mg orodisperzibilne tablete desloratadin
Neoclarityn orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older.
Zdravilo Neoclarityn orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 6 let in več.
What Neoclarityn oral solution is and what it is used for
Kaj je zdravilo Neoclarityn peroralna raztopina in za kaj ga uporabljamo
Neoclarityn oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older.
Zdravilo Neoclarityn peroralna raztopina lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 1 leto in več.
Neoclarityn 5 mg orodispersible tablets desloratadine
Neoclarityn 5 mg orodisperzibilne tablete desloratadin
Neoclarityn 2.5 mg orodispersible tablet
Neoclarityn 2,5 mg orodisperzibilna tableta
Neoclarityn orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Neoclarityn orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
Neoclarityn relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Neoclarityn lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
What Neoclarityn orodispersible tablet contains
Kaj vsebuje zdravilo Neoclarityn orodisperzibilna tableta
The recommended dose is 2.5 ml (½ of a 5 ml spoonful) of oral solution once a day.
Priporočeni odmerek zdravila Neoclarityn je 10 ml (5 mg) peroralne raztopine enkrat na dan.
Date of first authorisation: 21 February 2005 Date of latest renewal: 19 January 2010
Datum prve odobritve: 21. februar 2005 Datum zadnjega podaljšanja: 19. januar 2010
How to prepare a new bottle of medicine for first time use:
Kako pripraviti novo steklenico zdravila za prvo uporabo:
Follow the instructions below:
Upoštevajte spodnja navodila:
Important information about instructions for use:
Pomembna informacija o navodilih za uporabo:
The dose that your doctor prescribes you should be given in ml of suspension and not in mg.
Odmerek, ki vam ga predpiše zdravnik, je treba dati v ml suspenzije in ne v mg.
The clinical study was open-labelled and uncontrolled.
Klinična študija je bila odprta in nenadzorovana.
Monitoring visits should be performed every 6 months; shorter intervals between visits are recommended in case of adverse events.
Kontrolni pregledi naj bod izvedeni vsakih 6 mesecev, krajši razmiki med posameznimi obiski so priporočljivi v primeru neželenih dogodkov.
Orfadin must not be injected.
Zdravila Orfadin se ne sme injicirati.
Re-dispersing is required before each use by vigorous shaking.
Pred vsako uporabo je potrebna redisperzija z močnim stresanjem.
Turn the bottle to an upright position again.
Obrnite steklenico spet v pokončen položaj.
The dose should be withdrawn and administered immediately after re-dispersion.
Odmerek je treba izvleči in dati takoj po redisperziji.
Orfadin should not be used during pregnancy unless the clinical condition of the woman requires treatment with nitisinone.
Zdravila Orfadin ne smete uporabljati med nosečnostjo, razen če klinično stanje nosečnice zahteva zdravljenje z nitizinonom.
In an international survey of patients with HT-1 on treatment with dietary restriction alone, it was found that HCC had been diagnosed in 18% of all patients aged 2 years and above.
V mednarodni študiji pri bolnikih s HT-1 o zdravljenju zgolj s predpisano dieto so ugotovili, da je bila diagnoza HCK postavljena pri 18 % vseh bolnikov, starih 2 leti in več.
However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4“Possible side effects”).
Če pa se pri jemanju pojavijo neželeni učinki, ki vplivajo na vid, ne smete voziti ali upravljati strojev, dokler se vaš vid ne normalizira (glejte poglavje 4 »Možni neželeni učinki«).
From clinical study and post marketing data there are no indications that the safety profile is different in different subsets of the paediatric population or different from the safety profile in adult patients.
Iz kliničnih študij in iz podatkov v obdobju trženja zdravila se pri nobeni indikaciji ne pokaže različen varnostni profil pri različnih podskupinah pediatričnih bolnikov ali drugačen varnostni profil glede na odrasle bolnike.
A population pharmacokinetic analysis has been conducted on a group of 207 HT-1 patients.
Populacijske farmakokinetične analize so bile izvedene na skupini 207 bolnikov s HT-1.
Orfadin is also available as a 4 mg/ml oral suspension for paediatric patients who have difficulties swallowing capsules.
Zdravilo Orfadin je na voljo tudi kot 4 mg/ml peroralna suspenzija za pediatrične bolnike, ki imajo težave pri požiranju kapsul.
What Orfadin is and what it is used for
Kaj je zdravilo Orfadin in za kaj ga uporabljamo
What Orfadin is and what it is used for What you need to know before you take Orfadin How to take Orfadin
Kaj je zdravilo Orfadin in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Orfadin Kako jemati zdravilo Orfadin
Age at onset of symptoms 1 year 2 years < 2 months > 2-6 months > 6 months
Starost pri pojavu simptomov 1 leto 2 leti < 2 meseca > 2-6 mesecev > 6 mesecev
Oral suspension 90 ml
peroralna suspenzija 90 ml
Orfadin may interfere with the effect of other medicines, such as: - Medicines for epilepsy (such as phenytoin) - Medicines against blood clotting (such as warfarin)
Zdravilo Orfadin lahko vpliva na delovanje drugih zdravil, kot so: - zdravila za epilepsijo (kot je fenitoin) - zdravila proti strjevanju krvi (kot je varfarin)
Do not attach a needle to the syringe.
Na brizgo ne pritrdite igle.
The dose recommendation in mg/kg body weight is the same in children and adults.
Pediatrična populacija Priporočeni odmerek v mg/kg telesne mase je enak za otroke in odrasle.
It is recommended that the oral suspension is taken with food.
Priporočljivo je, da se peroralna suspenzija jemlje s hrano.
It is important that you use the correct oral syringe when taking the medicine.
Pomembno je, da uporabite pravo brizgo za peroralno dajanje , ko vzamete zdravilo.
Follow-up by your doctor should be performed every 6 months.
Vsakih 6 mesecev mora zdravnik opraviti kontrolni pregled.
Other medicines and Orfadin
Druga zdravila in zdravilo Orfadin
Age at start of treatment 2 years 4 years 6 years
Starost na začetku zdravljenja 2 leti 4 leta 6 let
If you start treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment.
Če boste zdravljenje začeli z jemanjem tega zdravila s hrano je priporočljivo, da tako nadaljujete ves čas zdravljenja.
How to prepare a dose of medicine
Kako pripraviti odmerek zdravila
Increase in serum alpha-fetoprotein concentration may be a sign of inadequate treatment.
Povečanje koncentracije alfa-fotoproteina je lahko znak neustreznega zdravljenja.
The bottle adapter should not be removed.
Nastavek za steklenico se ne sme odstraniti.
This is because the oral syringe which is used to withdraw the correct dose from the bottle is marked in ml.
To pa zato, ker ima brizga za peroralno dajanje, ki se uporablja za odvzem pravilnega odmerka iz steklenice, oznake v ml.
No information about specific treatment of overdose is available.
Ni podatkov o specifičnosti zdravljenja v primeru prevelikega odmerjanja.
Food does not influence the bioavailability of nitisinone oral suspension, but intake together with food decreases the absorption rate and consequently leads to lower fluctuations in serum concentrations within a dosage interval.
Hrana ne vpliva na biološko uporabnost peroralne suspenzije nitizinona, vendar jemanje skupaj s hrano zmanjša hitrost absorpcije in posledično povzroči nižje fluktuacije v serumskih koncentracijah znotraj intervala odmerjanja.
Pharmacotherapeutic group: Other alimentary tract and metabolism products, Various alimentary tract and metabolism products, ATC code: A16A X04.
Farmakoterapevtska skupina: Druga zdravila za bolezni prebavil in presnove, razna zdravila za bolezni prebavil in presnove, oznaka ATC: A16A X04.
Contents of the pack and other information What Orfadin contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Orfadin
Your doctor, pharmacist or nurse will advise which oral syringe to use depending on the dose that has been prescribed.
Zdravnik, farmacevt ali medicinska sestra vam bodo svetovali, katero brizgo za peroralno dajanje uporabite, glede na odmerek, ki vam je bil predpisan.
Orfadin blocks the breakdown of tyrosine and the harmful substances are not formed.
Zdravilo Orfadin zaustavi razgraditev tirozina in prepreči nastanek škodljivih snovi.
If the vision is affected the patient should not drive or use machines until the event has subsided.
Če je prizadet vid, naj bolnik ne vozi in ne upravlja strojev, dokler neželen učinek ne izzveni.
2 mg: Store in a refrigerator.
2 mg: Shranjujte v hladilniku.
The bottle may be stored at a temperature not above 25°C or in the refrigerator.
Steklenica se lahko shranjuje pri temperaturi do 25 °C ali v hladilniku.
What you need to know before you take Orfadin Do not take Orfadin
Kaj morate vedeti, preden boste vzeli zdravilo Orfadin Ne jemljite zdravila Orfadin
The bottle may be stored at room temperature (not above 25°C).
Steklenico lahko shranjujete pri sobni temperaturi (do 25 °C).
Do not breast-feed while taking this medicine, see section “Do not take Orfadin”.
Med jemanjem tega zdravila ne smete dojiti, glejte poglavje »Ne jemljite zdravila Orfadin«.
The newborn baby's blood levels of bilirubin (a substance that causes the yellowing of the skin in high levels) will be closely monitored.
Novorojenčkove ravni bilirubina (snovi, ki povzroča porumenelost kože in visoke ravni) v krvi bodo natančno spremljali.
It is important to carefully follow the instructions given in section 6.6 for preparation and administration of the dose, in order to ensure the dosing accuracy.
Pomembno je, da se točno upošteva navodila, dana v poglavju 6.6, za pripravo in dajanje odmerka, da se zagotovi natančnost odmerjanja.
The dose should be administered in the mouth immediately (without dilution) in order to avoid caking in the oral syringe.
Odmerek je treba dati v usta takoj (brez redčenja), da se prepreči strjevanje v peroralni brizgi.
The adverse reactions listed below by MedDRA system organ class and absolute frequency, are based on data from a clinical trial and post-marketing use.
Neželeni učinki, ki so navedeni spodaj in so razvrščene na podlagi organskih sistemov in absolutne pogostnosti, temeljijo na podatkih iz kliničnega preskušanja in uporabe v obdobju trženja.
Each pack contains 1 bottle.
Eno pakiranje vsebuje 1 plastenko.
Remove the bottle from the refrigerator.
Vzemite steklenico iz hladilnika.
Each bottle contains 90 ml oral suspension.
Vsaka steklenica vsebuje 90 ml peroralne suspenzije.
HDPE bottle with a tamper-proof closure of LDPE, containing 60 capsules.
Plastenka iz HDPE z zaščitno zaporko iz LDPE, ki vsebuje 60 kapsul.
Do not throw away any medicines via wastewater or household waste.
Zdravila ne smete odvreči v odpadne vode ali md gospodinjske odpadke.
Do not use this medicine after the expiry date which is stated on the bottle and the carton after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake »EXP«.
A close monitoring of the plasma levels of bilirubin in the newborn patient is therefore of great importance.
Pri novorojenih bolnikih je zato zelo pomembno natančno spremljanje ravni bilirubina v plazmi.
Orfadin with food
Zdravilo Orfadin skupaj s hrano